ECSP034639A - Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos - Google Patents

Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos

Info

Publication number
ECSP034639A
ECSP034639A EC2003004639A ECSP034639A ECSP034639A EC SP034639 A ECSP034639 A EC SP034639A EC 2003004639 A EC2003004639 A EC 2003004639A EC SP034639 A ECSP034639 A EC SP034639A EC SP034639 A ECSP034639 A EC SP034639A
Authority
EC
Ecuador
Prior art keywords
pharmacologically active
pharmaceutical compositions
active agent
agent
oral supply
Prior art date
Application number
EC2003004639A
Other languages
English (en)
Inventor
Joseph M Ault
Moise Azria
Simon David Bateman
Joseph Sikora
Gregory Sparta
Rebecca Fai-Ying Yang
Jie Xiao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP034639A publication Critical patent/ECSP034639A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se dan a conocer composiciones farmacéuticas sólidas adecuadas para el suministro oral de agentes farmacológica mente activos, por ejemplo péptidos, las cuales comprenden una cantidad terapéuticamente efectiva de un agente farmacológica mente activo, una crospovidona o providona, y un agente de suministro para este agente farmacológica mente activo,. Las composiciones proporcionan una excelente biodisponiblidad oral de los agentes farmacológica mente activos, en particular calcitonina
EC2003004639A 2000-12-06 2003-06-04 Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos ECSP034639A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US25172900P 2000-12-06 2000-12-06

Publications (1)

Publication Number Publication Date
ECSP034639A true ECSP034639A (es) 2003-07-25

Family

ID=22953160

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004639A ECSP034639A (es) 2000-12-06 2003-06-04 Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos

Country Status (26)

Country Link
US (1) US7049283B2 (es)
EP (1) EP1341526B1 (es)
JP (2) JP4898078B2 (es)
KR (1) KR100847695B1 (es)
CN (1) CN1304048C (es)
AT (1) ATE513541T1 (es)
AU (2) AU3454702A (es)
BR (2) BRPI0115965B1 (es)
CA (1) CA2436599C (es)
CY (1) CY1112562T1 (es)
CZ (1) CZ305418B6 (es)
DK (1) DK1341526T3 (es)
EC (1) ECSP034639A (es)
ES (1) ES2367009T3 (es)
HU (1) HU230632B1 (es)
IL (2) IL155992A0 (es)
MX (1) MXPA03005096A (es)
NO (1) NO332936B1 (es)
NZ (1) NZ526196A (es)
PL (1) PL209703B1 (es)
PT (1) PT1341526E (es)
RU (1) RU2287999C2 (es)
SI (1) SI1341526T1 (es)
SK (1) SK287613B6 (es)
WO (1) WO2002045754A2 (es)
ZA (1) ZA200304295B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
CA2446929C (en) * 2001-06-01 2013-04-09 Novartis Ag Orally administering parathyroid hormone and calcitonin
US20050054557A1 (en) * 2002-05-09 2005-03-10 Goldberg Michael M. Compositions for delivering parathyroid hormone and calcitonin
TW200403052A (en) * 2002-07-17 2004-03-01 Novartis Ag Use of organic compounds
PE20040724A1 (es) * 2002-08-01 2004-12-06 Novartis Ag Composicion para la administracion oral de calcitonina
PL1603553T3 (pl) * 2003-03-17 2012-04-30 Japan Tobacco Inc Kompozycje farmaceutyczne inhibitorów CETP
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
PT1651248E (pt) * 2003-07-11 2009-11-10 Novartis Ag Composições farmacêuticas para dose oral compreendendo um agente de administração na forma micronizada
PL1651249T3 (pl) * 2003-07-23 2013-04-30 Novartis Ag Zastosowanie kalcytoniny w zapaleniu kości i stawów
EP1663182B2 (en) * 2003-09-12 2019-11-20 Amgen Inc. RAPID DISSOLUTION FORMULATION OF CINACALCET HCl
NZ551597A (en) * 2004-05-19 2010-11-26 Emisphere Tech Inc Topical cromolyn formulations
GB0422644D0 (en) * 2004-10-12 2004-11-10 Novartis Ag Organic compounds
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US20080153779A1 (en) * 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
WO2007005995A2 (en) * 2005-07-05 2007-01-11 Emisphere Technologies, Inc. Compositions for buccal delivery of human growth hormone
AU2006292337B8 (en) 2005-09-19 2013-02-07 Emisphere Technologies, Inc. Crystalline forms of the di-sodium salt of N-(5-chlorosalicyloyl)-8-aminocaprylic acid
GB0522566D0 (en) 2005-11-04 2005-12-14 Novartis Ag Organic compounds
US20080255048A1 (en) * 2005-11-17 2008-10-16 Moise Azria Pharmaceutical Composition
EP1991241A4 (en) * 2006-02-23 2009-07-08 Iomedix Sleep Internat Srl COMPOSITIONS AND METHODS FOR INTRODUCING AND MAINTAINING HIGH-QUALITY SLEEPING
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
KR101524880B1 (ko) * 2006-08-31 2015-06-01 노파르티스 아게 Ｈｇｈ를 포함하는 경구 전달용 제약 조성물
CA2572004A1 (en) * 2006-12-08 2008-06-08 Bernard Charles Sherman Tablets comprising entacapone and crospovidone
ES2365648T3 (es) * 2007-03-02 2011-10-07 Novartis Ag Administración oral de una calcitonina.
WO2009059188A1 (en) 2007-11-02 2009-05-07 Emisphere Technologies, Inc. Method of treating vitamin b12 deficiency
CN102123697B (zh) * 2008-08-18 2015-06-10 安特拉贝欧有限公司 用于口服给予蛋白质的方法和组合物
EP2762150A1 (en) * 2009-03-12 2014-08-06 Nordic Bioscience A/S Treatment of Diabetes and Metabolic Syndrome
KR101811376B1 (ko) * 2010-06-09 2017-12-22 에미스페어 테크놀로지스, 인코포레이티드 경구용 철 결핍증 치료
MX345501B (es) 2010-12-16 2017-02-02 Novo Nordisk As Composiciones solidas que comprenden agonista de glp-1 y sal del acido n-(8-(2-hidroxibenzoil)amino)caprilico.
KR101972836B1 (ko) 2011-04-12 2019-04-29 노보 노르디스크 에이/에스 이중 아실화된 ｇｌｐ-1 유도체
EP2827885B1 (en) 2012-03-22 2018-08-15 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
HRP20190489T1 (hr) 2012-03-22 2019-05-03 Novo Nordisk A/S Pripravci koji sadrže sredstvo za unošenje i njihova priprava
WO2013139695A1 (en) 2012-03-22 2013-09-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
US9993430B2 (en) 2012-06-20 2018-06-12 Novo Nordisk A/S Tablet formulation comprising semaglutide and a delivery agent
SMT201800492T1 (it) 2013-05-02 2018-11-09 Novo Nordisk As Dosaggio orale di composti di glp-1
CN104961687B (zh) * 2015-06-03 2017-07-25 苏州维泰生物技术有限公司 1,2‑二嗪衍生物及其制剂、用途
BR112017022857B1 (pt) * 2015-07-08 2023-09-26 Research & Business Foundation Sungkyunkwan University Composto, método para preparar o composto, uso de uma composição
WO2017064538A1 (en) * 2015-10-16 2017-04-20 Nobel Ilac Sanayii Ve Ticaret A.S. Pharmaceutical compositions of nilotinib hydrochloride
CN107080739A (zh) * 2017-04-17 2017-08-22 深圳市泛谷药业股份有限公司 一种用于口服给药的固体快速释放布南色林片及其制备方法
EP4299118A3 (en) 2018-02-02 2024-04-10 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
JP2021054781A (ja) * 2019-09-26 2021-04-08 デボン エルエス，リミテッド 共結晶形エフィナコナゾール、及びその製造方法
KR102301743B1 (ko) * 2020-12-29 2021-09-13 대봉엘에스 주식회사 에피나코나졸 경구용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015633A (en) 1987-04-27 1991-05-14 E. R. Squibb & Sons, Inc. Method for inhibiting loss of cognitive functions employing an ace inhibitor
US5756450A (en) 1987-09-15 1998-05-26 Novartis Corporation Water soluble monoesters as solubilisers for pharmacologically active compounds and pharmaceutical excipients and novel cyclosporin galenic forms
US5002771A (en) 1989-02-06 1991-03-26 Rorer Pharmaceutical Corp. Calcitonin suppository formulations
IT1238072B (it) 1990-01-19 1993-07-03 Sclavo Spa Composizioni farmaceutiche e forme di dosaggio per la somministrazione orale di calcitonina
JPH052771A (ja) * 1991-06-25 1993-01-08 Pioneer Electron Corp 光記録媒体
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
EP0800384B1 (en) 1994-12-14 2001-03-07 Enbalt Trading Limited Pharmaceutical tablet formulations for direct compression
BR9604880A (pt) * 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5972381A (en) 1996-06-28 1999-10-26 Schering Corporation Solid solution of an antifungal agent with enhanced bioavailability
EP0839526A3 (en) * 1996-10-31 1999-01-07 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation with fast buccal disintegration or dissolution
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP4975201B2 (ja) 1997-02-07 2012-07-11 エミスフェアー・テクノロジーズ・インク 化合物及び活性剤を送達するための組成物
RO121834B1 (ro) 1998-03-16 2008-06-30 Inhale Therapeutic Systems, Inc. Dispozitiv pentru administrarea unui agent activ
WO2000057857A1 (en) 1999-03-25 2000-10-05 Yuhan Corporation Rapidly disintegrable tablet for oral administration
NZ534409A (en) * 1999-04-05 2006-03-31 Emisphere Tech Inc Disodium salts, monohydrates, and ethanol solvates for delivering active agents
WO2000059480A1 (en) * 1999-04-05 2000-10-12 Emisphere Technologies, Inc. Lyophilized solid dosage forms and methods of making

Also Published As

Publication number Publication date
CY1112562T1 (el) 2016-02-10
HUP0302319A3 (en) 2013-04-29
AU3454702A (en) 2002-06-18
JP2009185052A (ja) 2009-08-20
ES2367009T3 (es) 2011-10-27
DK1341526T3 (da) 2011-10-03
EP1341526B1 (en) 2011-06-22
IL155992A (en) 2008-04-13
BRPI0115965B1 (pt) 2017-09-26
AU2002234547B2 (en) 2005-03-24
PL362247A1 (en) 2004-10-18
NO332936B1 (no) 2013-02-04
MXPA03005096A (es) 2003-09-05
EP1341526A2 (en) 2003-09-10
HK1059565A1 (en) 2004-07-09
KR20040018309A (ko) 2004-03-03
WO2002045754A3 (en) 2003-01-03
US20020123459A1 (en) 2002-09-05
KR100847695B1 (ko) 2008-07-23
PT1341526E (pt) 2011-09-01
HUP0302319A2 (hu) 2003-11-28
US7049283B2 (en) 2006-05-23
CZ305418B6 (cs) 2015-09-09
ZA200304295B (en) 2004-05-10
RU2287999C2 (ru) 2006-11-27
HU230632B1 (hu) 2017-05-29
PL209703B1 (pl) 2011-10-31
CZ20031566A3 (cs) 2003-09-17
SK6882003A3 (en) 2004-01-08
WO2002045754A2 (en) 2002-06-13
NO20032511L (no) 2003-06-03
CA2436599A1 (en) 2002-06-13
JP2004515480A (ja) 2004-05-27
CA2436599C (en) 2011-01-25
BR0115965A (pt) 2003-10-28
IL155992A0 (en) 2003-12-23
CN1304048C (zh) 2007-03-14
NZ526196A (en) 2005-01-28
JP4898078B2 (ja) 2012-03-14
SI1341526T1 (sl) 2011-10-28
ATE513541T1 (de) 2011-07-15
SK287613B6 (sk) 2011-04-05
NO20032511D0 (no) 2003-06-03
CN1479612A (zh) 2004-03-03

Similar Documents

Publication Publication Date Title
ECSP034639A (es) Composiciones farmaceuticas para el suministro oral de agente farmacológicamente activos
ID27504A (id) Formulasi oral baru
ITMI20001173A0 (it) Composizioni farmaceutiche a rilascio prolungato per la somministrazione parenterale di sostanze idrofile biologicamente attiva.
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
DE602004023093D1 (de) N mit einem abgabemittel in mikronisierter form
UY27532A1 (es) Forma de dosificación de liberación controlada dual.
BRPI0113331B8 (pt) derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
MXPA02003321A (es) Composiciones de liberacion controlada que comprenden nimesulida.
AR044775A1 (es) Composiciones farmaceuticas de atorvastatina
MX2007015480A (es) Formulaciones de dosificacion solida de medicamentos narcoticos que tienen adsorcion bucal mejorada.
PY0206703A (es) Metodo para fabricar una composicion farmaceutica de dosis baja que tiene una distribucion y potencia del farmaco uniformes
IT1255460B (it) Composizioni farmaceutiche in forma di microemulsioni o di dispersioni liposomiali bioadesive per la somministrazione transmucosale di sostanze peptidiche e di proteine farmacologicamente attive
DK1608349T3 (da) Oralt tilförselssystem omfattende et antibakterielt og et antiinflammatorisk middel
BR0112847A (pt) Uso de uma forma de dosagem sólida
ECSP014082A (es) Combinacion de secretagogos de hormona del crecimiento y antidepresivos
ES2150404T3 (es) Composiciones farmaceuticas de tizoxanida y nitozoxanida.
ES2194618T1 (es) Composicion oralmente desintegrable que comprende mirtazapina.
ECSP003685A (es) Formulaciones orales de liberacion controlada
TR200601092T1 (tr) İrbesartan etkin maddesi içeren yeni oral farmasötik formülasyonlar.
AR040764A1 (es) Formulaciones farmaceuticas de epinastina, pseudoefedrina y metilefedrina
FR2798288B1 (fr) Compositions vaccinales destinees a une administration par voie muqueuse
NO20034873D0 (no) Bredspektret 2-(amino)-benzoxazolsulfonamid HIV proteasehemmere
UY27122A1 (es) Una composición farmacéutica que comprende de 2 a 4 mg de 5-(a-(2-(n-metil-n-(2-piridil)amino)etoxi)bencil)tiazolidin-2,4-diona
GT200100223A (es) Composiciones hidroliticamente inestables.